193 related articles for article (PubMed ID: 36939801)
1. Increased Soluble Epoxide Hydrolase Activity Positively Correlates with Mortality in Heart Failure Patients with Preserved Ejection Fraction: Evidence from Metabolomics.
Peng L; Song Z; Zhao C; Abuduwufuer K; Wang Y; Wen Z; Ni L; Li C; Yu Y; Zhu Y; Jiang H; Shen J; Jiang X; Chen C; Zhang X; Wang DW
Phenomics; 2023 Feb; 3(1):34-49. PubMed ID: 36939801
[TBL] [Abstract][Full Text] [Related]
2. Glimepiride, a novel soluble epoxide hydrolase inhibitor, protects against heart failure via increasing epoxyeicosatrienoic acids.
Zhao C; Jiang X; Peng L; Zhang Y; Li H; Zhang Q; Wang Y; Yang F; Wu J; Wen Z; He Z; Shen J; Chen C; Wang DW
J Mol Cell Cardiol; 2023 Dec; 185():13-25. PubMed ID: 37871528
[TBL] [Abstract][Full Text] [Related]
3. Soluble epoxide hydrolase inhibitors and heart failure.
Qiu H; Li N; Liu JY; Harris TR; Hammock BD; Chiamvimonvat N
Cardiovasc Ther; 2011 Apr; 29(2):99-111. PubMed ID: 20433684
[TBL] [Abstract][Full Text] [Related]
4. Epoxyeicosatrienoic acid administration or soluble epoxide hydrolase inhibition attenuates renal fibrogenesis in obstructive nephropathy.
Noh MR; Jang HS; Salem FE; Ferrer FA; Kim J; Padanilam BJ
Am J Physiol Renal Physiol; 2023 Feb; 324(2):F138-F151. PubMed ID: 36475868
[TBL] [Abstract][Full Text] [Related]
5. Prognostic benefit of early diagnosis with exercise stress testing in heart failure with preserved ejection fraction.
Saito Y; Obokata M; Harada T; Kagami K; Wada N; Okumura Y; Ishii H
Eur J Prev Cardiol; 2023 Jul; 30(9):902-911. PubMed ID: 37094815
[TBL] [Abstract][Full Text] [Related]
6. Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BK(Ca) channels: implications for soluble epoxide hydrolase inhibition.
Larsen BT; Miura H; Hatoum OA; Campbell WB; Hammock BD; Zeldin DC; Falck JR; Gutterman DD
Am J Physiol Heart Circ Physiol; 2006 Feb; 290(2):H491-9. PubMed ID: 16258029
[TBL] [Abstract][Full Text] [Related]
7. Age and Sex Differences in Hearts of Soluble Epoxide Hydrolase Null Mice.
Jamieson KL; Keshavarz-Bahaghighat H; Darwesh AM; Sosnowski DK; Seubert JM
Front Physiol; 2020; 11():48. PubMed ID: 32116760
[TBL] [Abstract][Full Text] [Related]
8. Soluble epoxide hydrolase and TRPC3 channels jointly contribute to homocysteine-induced cardiac hypertrophy: Interrelation and regulation by C/EBPβ.
Zhou Y; Wang XC; Wei JH; Xue HM; Sun WT; He GW; Yang Q
Biochim Biophys Acta Mol Basis Dis; 2023 Apr; 1869(4):166643. PubMed ID: 36669577
[TBL] [Abstract][Full Text] [Related]
9. The involvement of soluble epoxide hydrolase in the development of cardiovascular diseases through epoxyeicosatrienoic acids.
Jiang S; Han S; Wang DW
Front Pharmacol; 2024; 15():1358256. PubMed ID: 38628644
[TBL] [Abstract][Full Text] [Related]
10. Distribution of soluble and microsomal epoxide hydrolase in the mouse brain and its contribution to cerebral epoxyeicosatrienoic acid metabolism.
Marowsky A; Burgener J; Falck JR; Fritschy JM; Arand M
Neuroscience; 2009 Oct; 163(2):646-61. PubMed ID: 19540314
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of soluble epoxide hydrolase increases coronary perfusion in mice.
Qin J; Sun D; Jiang H; Kandhi S; Froogh G; Hwang SH; Hammock BD; Wolin MS; Thompson CI; Hintze TH; Huang A
Physiol Rep; 2015 Jun; 3(6):. PubMed ID: 26071213
[TBL] [Abstract][Full Text] [Related]
12. Epoxyeicosatrienoic acids and soluble epoxide hydrolase: potential therapeutic targets for inflammation and its induced carcinogenesis.
Norwood S; Liao J; Hammock BD; Yang GY
Am J Transl Res; 2010 Jul; 2(4):447-57. PubMed ID: 20733953
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of soluble epoxide hydrolase ameliorates hyperhomocysteinemia-induced hepatic steatosis by enhancing β-oxidation of fatty acid in mice.
Yao L; Cao B; Cheng Q; Cai W; Ye C; Liang J; Liu W; Tan L; Yan M; Li B; He J; Hwang SH; Zhang X; Wang C; Ai D; Hammock BD; Zhu Y
Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G527-G538. PubMed ID: 30789748
[TBL] [Abstract][Full Text] [Related]
14. Preservation of epoxyeicosatrienoic acid bioavailability prevents renal allograft dysfunction and cardiovascular alterations in kidney transplant recipients.
Duflot T; Laurent C; Soudey A; Fonrose X; Hamzaoui M; Iacob M; Bertrand D; Favre J; Etienne I; Roche C; Coquerel D; Le Besnerais M; Louhichi S; Tarlet T; Li D; Brunel V; Morisseau C; Richard V; Joannidès R; Stanke-Labesque F; Lamoureux F; Guerrot D; Bellien J
Sci Rep; 2021 Feb; 11(1):3739. PubMed ID: 33580125
[TBL] [Abstract][Full Text] [Related]
15. Association of Diabetes Mellitus on Cardiac Remodeling, Quality of Life, and Clinical Outcomes in Heart Failure With Reduced and Preserved Ejection Fraction.
Yap J; Tay WT; Teng TK; Anand I; Richards AM; Ling LH; MacDonald MR; Chandramouli C; Tromp J; Siswanto BB; ; Zile M; McMurray J; Lam CSP
J Am Heart Assoc; 2019 Sep; 8(17):e013114. PubMed ID: 31431116
[TBL] [Abstract][Full Text] [Related]
16. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction.
Kraigher-Krainer E; Shah AM; Gupta DK; Santos A; Claggett B; Pieske B; Zile MR; Voors AA; Lefkowitz MP; Packer M; McMurray JJ; Solomon SD;
J Am Coll Cardiol; 2014 Feb; 63(5):447-56. PubMed ID: 24184245
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of soluble epoxide hydrolase preserves cardiomyocytes: role of STAT3 signaling.
Merkel MJ; Liu L; Cao Z; Packwood W; Young J; Alkayed NJ; Van Winkle DM
Am J Physiol Heart Circ Physiol; 2010 Feb; 298(2):H679-87. PubMed ID: 20008276
[TBL] [Abstract][Full Text] [Related]
18. Small Molecule Soluble Epoxide Hydrolase Inhibitors in Multitarget and Combination Therapies for Inflammation and Cancer.
Das Mahapatra A; Choubey R; Datta B
Molecules; 2020 Nov; 25(23):. PubMed ID: 33255197
[TBL] [Abstract][Full Text] [Related]
19. Ablation of soluble epoxide hydrolase reprogram white fat to beige-like fat through an increase in mitochondrial integrity, HO-1-adiponectin in vitro and in vivo.
Liu L; Puri N; Raffaele M; Schragenheim J; Singh SP; Bradbury JA; Bellner L; Vanella L; Zeldin DC; Cao J; Abraham NG
Prostaglandins Other Lipid Mediat; 2018 Sep; 138():1-8. PubMed ID: 30041041
[TBL] [Abstract][Full Text] [Related]
20. Sodium-glucose co-transporter 2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an updated systematic review and meta-analysis.
Wang Y; Gao T; Meng C; Li S; Bi L; Geng Y; Zhang P
Eur J Med Res; 2022 Dec; 27(1):314. PubMed ID: 36581880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
